Edwards Lifesciences Corp
UBS reiterated a Buy rating on Edwards Lifesciences (NYSE:EW) with a $110.00 price target, citing endpoint expectations. The stock trades at a P/E of 49.59, but is considered undervalued. Recent Q2 results showed $1.74B in sales, up 12.5%, and EPS of $0.78. Analysts have mixed views on the stock's outlook.
The FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.
FDA nominee Heidi Overton's confirmation vote delayed until after midterms. FDA reinstated advisory committees and updated safety monitoring. Two individuals charged in counterfeit Ozempic scheme. Egetis' Emcitate and BMS's Camzyos received approvals. PhRMA to welcome new CEO Eric Cantor. FDA adopted new data standards and updated forms. CDRH met MDUFA V commitments. Autus Valve approved for pediatric use.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning EW (Edwards Lifesciences Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent EW coverage spans regulation, financial news and technology.
In the last 30 days, EW insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($53K). The most active reporter was Lippis Daniel J., CVP, TAVR, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst rating reaffirmation with modest upside potential.
Potential revenue uplift from a novel pediatric heart valve and market differentiation.
Approval of a novel pediatric valve could be favorable for EW.
Positive regulatory clearance may boost sales and lift the stock.
Regulatory approval is positive but the modest price move suggests limited immediate impact.
AlphAI scores every news story that mentions EW with an AI model for sentiment and relevance, and aggregates insider trades from Edwards Lifesciences Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS reiterated a Buy rating on Edwards Lifesciences (NYSE:EW) with a $110.00 price target, citing endpoint expectations. The stock trades at a P/E of 49.59, but is considered undervalued. Recent Q2 results showed $1.74B in sales, up 12.5%, and EPS of $0.78. Analysts have mixed views on the stock's outlook.
2 min readThe FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.
2 min readFDA nominee Heidi Overton's confirmation vote delayed until after midterms. FDA reinstated advisory committees and updated safety monitoring. Two individuals charged in counterfeit Ozempic scheme. Egetis' Emcitate and BMS's Camzyos received approvals. PhRMA to welcome new CEO Eric Cantor. FDA adopted new data standards and updated forms. CDRH met MDUFA V commitments. Autus Valve approved for pediatric use.
3 min readEdwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
3 min readNike (NKE) reported mixed Q1 results, missing revenue estimates but beating earnings. Synaptics (SYNA) agreed to be acquired by ON Semiconductor (ON) for $123 per share. Edwards Lifesciences (EW) received FDA approval for a pediatric valve. AsiaStrategy (SORA) and Mangoceuticals (MGRX) made announcements, causing after-hours price swings.
2 min readEdwards Lifesciences (EW) received FDA approval for the AUTUS Size-Adjustable Valve, a pediatric pulmonary valve that can be expanded as a child grows. The approval was based on a study showing 100% of patients had no device-related complications at 30 days and favorable outcomes at one year. The valve aims to reduce the need for repeat surgeries in children with congenital heart disease. EW shares closed at $85.19, down 1.31%, and were up 0.87% in overnight trading.
2 min readEdwards Lifesciences (EW) received FDA approval for AUTUS, a pediatric pulmonary valve. The approval followed a pivotal study meeting safety and effectiveness endpoints, expanding the company's structural heart offerings into pediatric care.
1 min readEdwards Lifesciences (EW) updated its feasibility study for the SAPIEN M3 System, a device for treating mitral regurgitation. The study, completed but recently updated, aims to demonstrate safety and efficacy, paving the way for larger trials. Progress is significant for Edwards' mitral program and its competition in the transcatheter valve market.
1 min readCMS expanded Medicare coverage for Edwards Lifesciences' TAVR procedure to asymptomatic severe aortic stenosis patients. The company reiterated its 10-11% sales growth guidance. Shares (EW) fell 2.7% to $84.37. Analysts see upside, with Jefferies raising its price target to $105.
2 min readBD appointed Gary Sorsher, former Chief Quality Officer at Edwards Lifesciences, as its new Executive Vice President and Chief Quality Officer. Sorsher brings over 30 years of experience in quality roles. The move follows Jeffrey Silvestri's planned retirement. BD's CEO highlighted Sorsher's global experience and focus on continuous improvement. Edwards Lifesciences received FDA clearance for its Ecliptis left atrial appendage exclusion system, entering the surgical stroke-prevention market. BD
2 min read
